As previously presented, gedatolisib + palbociclib + fulvestrant ('gedatolisib triplet”) and gedatolisib + fulvestrant ('gedatolisib doublet”) reduced the risk of disease progression or death versus ...

Scientists find finerenone may stimulate ovarian follicles and help restore fertility in women with POI, offering a potential ...

Second clinical candidate from HUTCHMED’s next-generation ATTC platform —— Leveraging synergy through simultaneous inhibition of PAM pathway and EGFR signaling — Hong Kong, Shanghai & Florham Park, NJ ...

TD Cowen 46th Annual Health Care Conference March 4, 2026 10:30 AM ESTCompany ParticipantsBrian Sullivan - Co-Founder, Chairman ...

Premature ovarian insufficiency (POI) affects 1–3% of women and has limited treatment options. Researchers report that ...

Hong Kong, Shanghai Friday, March 6, 2026, 10:00 Hrs [IST] ...

Premature ovarian insufficiency (POI) is a clinically significant cause of infertility that affects between 1 to 3% of women of childbearing age ...

Severe bacterial pneumonia remains a major cause of death in critically ill patients, largely due to impaired early immune responses.

Sepsis and severe pneumonia are frequently accompanied by disruption of the gut microbiota, leading to immune dysfunction and ...

A recent review identifies interleukin-36 (IL-36) as a transformative driver of vascular inflammation, revealing that serum ...

NEW YORK – Hutchmed on Wednesday said it started a Phase I/IIa trial of its antibody-targeted therapy conjugate (ATTC) HMPL-A580 in patients with unresectable, advanced or metastatic solid tumors.

CEO and co-founder Brian Sullivan outlined the company’s clinical programs, regulatory progress, and commercial launch preparations for gedatolisib during a fireside chat at TD Cowen’s 46th Annual ...